• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

EPs 7630治疗儿童和青少年急性支气管炎的疗效和耐受性——一项关于来自香叶天竺葵根的草药制剂的随机、双盲、安慰剂对照多中心试验

Efficacy and tolerability of EPs 7630 in children and adolescents with acute bronchitis - a randomized, double-blind, placebo-controlled multicenter trial with a herbal drug preparation from Pelargonium sidoides roots.

作者信息

Kamin W, Maydannik V, Malek F A, Kieser M

机构信息

University Hospital Pediatrics, Mainz, Germany.

出版信息

Int J Clin Pharmacol Ther. 2010 Mar;48(3):184-91. doi: 10.5414/cpp48184.

DOI:10.5414/cpp48184
PMID:20197012
Abstract

OBJECTIVE

The study aim was to demonstrate the efficacy and to investigate the tolerability of EPs 7630, a herbal drug preparation from Pelargonium sidoides roots, in the treatment of patients (1 - 18 years) with acute bronchitis outside the strict indication for antibiotics.

MATERIALS AND METHODS

A total of 200 patients were randomized to receive either active drug containing EPs 7630 (1 - 6 years: 3 x 10 drops/d; > 6 - 12 years: 3 x 20 drops/d; > 12 - 18 years: 3 x 30 drops/d) or placebo for 7 consecutive days.

PRIMARY OUTCOME MEASURE

change in the total score of bronchitis-specific symptoms (BSS) from Day 0 to Day 7. Main secondary outcome measures: treatment outcome, patients' satisfaction with treatment, onset of effect, bed rest.

RESULTS

From baseline to Day 7, the mean BSS score improved significantly more for EPs 7630 compared with placebo (3.4 +/- 1.8 vs. 1.2 +/- 1.8 points, p < 0.0001). On Day 7, treatment outcome was significantly better (p < 0.0001), satisfaction with treatment more pronounced (77.6% vs. 25.8%, p < 0.0001), onset of effect faster, and time of bed rest shorter as compared with placebo. Tolerability was similarly good in both groups. All adverse events were assessed as non-serious.

CONCLUSION

EPs 7630 was shown to be efficacious and safe in the treatment of acute bronchitis in children and adolescents outside the strict indication for antibiotics with patients treated with EPs 7630 perceiving a more favorable course of the disease and a good tolerability as compared with placebo.

摘要

目的

本研究旨在证明从香叶天竺葵根中提取的草药制剂EPs 7630在治疗无严格抗生素使用指征的1 - 18岁急性支气管炎患者中的疗效,并调查其耐受性。

材料与方法

总共200名患者被随机分为两组,一组连续7天接受含EPs 7630的活性药物治疗(1 - 6岁:每日3次,每次10滴;6 - 12岁:每日3次,每次20滴;12 - 18岁:每日3次,每次30滴),另一组接受安慰剂治疗。

主要观察指标

从第0天到第7天支气管炎特异性症状(BSS)总分的变化。主要次要观察指标:治疗结果、患者对治疗的满意度、起效时间、卧床休息时间。

结果

从基线到第7天,与安慰剂相比,EPs 7630组的平均BSS评分改善更为显著(3.4±1.8分对1.2±1.8分,p<0.0001)。在第7天,与安慰剂相比,治疗结果显著更好(p<0.0001),对治疗的满意度更高(77.6%对25.8%,p<0.0001),起效更快,卧床休息时间更短。两组的耐受性同样良好。所有不良事件均被评估为不严重。

结论

在治疗无严格抗生素使用指征的儿童和青少年急性支气管炎方面,EPs 7630被证明是有效且安全的,与安慰剂相比,接受EPs 7630治疗的患者感觉疾病进程更有利,耐受性良好。

相似文献

1
Efficacy and tolerability of EPs 7630 in children and adolescents with acute bronchitis - a randomized, double-blind, placebo-controlled multicenter trial with a herbal drug preparation from Pelargonium sidoides roots.EPs 7630治疗儿童和青少年急性支气管炎的疗效和耐受性——一项关于来自香叶天竺葵根的草药制剂的随机、双盲、安慰剂对照多中心试验
Int J Clin Pharmacol Ther. 2010 Mar;48(3):184-91. doi: 10.5414/cpp48184.
2
Treatment of acute bronchitis with EPs 7630: randomized, controlled trial in children and adolescents.用EPs 7630治疗急性支气管炎:儿童和青少年的随机对照试验
Pediatr Int. 2012 Apr;54(2):219-26. doi: 10.1111/j.1442-200X.2012.03598.x.
3
Treatment of acute bronchitis with a liquid herbal drug preparation from Pelargonium sidoides (EPs 7630): a randomised, double-blind, placebo-controlled, multicentre study.用来自香叶天竺葵的液体草药制剂(EPs 7630)治疗急性支气管炎:一项随机、双盲、安慰剂对照、多中心研究。
Curr Med Res Opin. 2007 Feb;23(2):323-31. doi: 10.1185/030079906X167318.
4
Efficacy and tolerability of EPs 7630 tablets in patients with acute bronchitis: a randomised, double-blind, placebo-controlled dose-finding study with a herbal drug preparation from Pelargonium sidoides.EP7630 片治疗急性支气管炎的疗效和耐受性:一项随机、双盲、安慰剂对照的剂量探索研究,采用西洋蒲公英草药制剂。
Curr Med Res Opin. 2010 Jun;26(6):1413-22. doi: 10.1185/03007991003798463.
5
Pelargonium sidoides preparation (EPs 7630) in the treatment of acute bronchitis in adults and children.香叶天竺葵制剂(EPs 7630)用于治疗成人和儿童的急性支气管炎。
Phytomedicine. 2007;14 Suppl 6:69-73. doi: 10.1016/j.phymed.2006.11.015. Epub 2006 Dec 20.
6
Efficacy and tolerability of EPs 7630 in patients (aged 6-18 years old) with acute bronchitis.EP7630 治疗急性支气管炎(6-18 岁)患者的疗效和耐受性。
Acta Paediatr. 2010 Apr;99(4):537-43. doi: 10.1111/j.1651-2227.2009.01656.x. Epub 2010 Jan 11.
7
Treatment of acute bronchitis in adults with a pelargonium sidoides preparation (EPs 7630): a randomized, double-blind, placebo-controlled trial.用香叶天竺葵制剂(EPs 7630)治疗成人急性支气管炎:一项随机、双盲、安慰剂对照试验。
Explore (NY). 2005 Nov;1(6):437-45. doi: 10.1016/j.explore.2005.08.009.
8
Efficacy and safety of an extract of Pelargonium sidoides (EPs 7630) in adults with acute bronchitis. A randomised, double-blind, placebo-controlled trial.南非天竺葵提取物(EPs 7630)治疗成人急性支气管炎的疗效与安全性:一项随机、双盲、安慰剂对照试验
Phytomedicine. 2003;10 Suppl 4:7-17. doi: 10.1078/1433-187x-00308.
9
Efficacy of a pelargonium sidoides preparation in patients with the common cold: a randomized, double blind, placebo-controlled clinical trial.香叶天竺葵制剂治疗普通感冒患者的疗效:一项随机、双盲、安慰剂对照临床试验。
Explore (NY). 2007 Nov-Dec;3(6):573-84. doi: 10.1016/j.explore.2007.09.004.
10
EPs 7630 improves acute bronchitic symptoms and shortens time to remission. Results of a randomised, double-blind, placebo-controlled, multicentre trial.EP7630可改善急性支气管炎症状并缩短缓解时间。一项随机、双盲、安慰剂对照、多中心试验的结果。
Planta Med. 2008 May;74(6):686-92. doi: 10.1055/s-2008-1074519. Epub 2008 Apr 30.

引用本文的文献

1
Phytotherapy for acute respiratory tract infections in children: a systematically conducted, comprehensive review.儿童急性呼吸道感染的植物疗法:一项系统开展的综合综述。
Front Pediatr. 2025 May 1;13:1423250. doi: 10.3389/fped.2025.1423250. eCollection 2025.
2
Multiple mechanisms enable broad-spectrum activity of the root extract EPs 7630 against acute respiratory tract infections.多种机制使根提取物EPs 7630对急性呼吸道感染具有广谱活性。
Front Pharmacol. 2024 Oct 14;15:1455870. doi: 10.3389/fphar.2024.1455870. eCollection 2024.
3
Medicinal Plants in the Treatment of Respiratory Diseases and their Future Aspects.
药用植物在呼吸系统疾病治疗中的应用及其未来展望
Recent Pat Biotechnol. 2025;19(1):2-18. doi: 10.2174/0118722083278561231212072408.
4
and effects of root extract EPs 7630 and selected constituents against SARS-CoV-2 B.1, Delta AY.4/AY.117 and Omicron BA.2.以及根提取物EPs 7630和选定成分对严重急性呼吸综合征冠状病毒2(SARS-CoV-2)B.1、德尔塔AY.4/AY.117和奥密克戎BA.2的作用。
Front Pharmacol. 2023 Jul 26;14:1214351. doi: 10.3389/fphar.2023.1214351. eCollection 2023.
5
Effects of EPs 7630 on the duration of inability to work in acute bronchitis - a meta-analysis.EPs 7630对急性支气管炎患者误工时长的影响——一项荟萃分析
Multidiscip Respir Med. 2023 Jun 13;18(1):914. doi: 10.4081/mrm.2023.914. eCollection 2023 Jan 17.
6
Safety of extract EPs 7630 in young children with acute bronchitis.EPs 7630提取物在患有急性支气管炎的幼儿中的安全性。
Front Pediatr. 2023 Feb 14;11:1107984. doi: 10.3389/fped.2023.1107984. eCollection 2023.
7
Polyphenolic promiscuity, inflammation-coupled selectivity: Whether PAINs filters mask an antiviral asset.多酚的混杂性、炎症耦合选择性:“PAINs”过滤器是否掩盖了一种抗病毒特性。
Front Pharmacol. 2022 Oct 21;13:909945. doi: 10.3389/fphar.2022.909945. eCollection 2022.
8
The efficacy and safety of DW1601 in patients with acute bronchitis: a multi-center, randomized, double-blind, phase III clinical trial.DW1601 治疗急性支气管炎的疗效和安全性:一项多中心、随机、双盲、III 期临床试验。
Korean J Intern Med. 2022 Nov;37(6):1195-1204. doi: 10.3904/kjim.2022.104. Epub 2022 Sep 26.
9
Effects of Pelargonium sidoides extract EPs 7630 on acute cough and quality of life - a meta-analysis of randomized, placebo-controlled trials.南非钩麻提取物EPs 7630对急性咳嗽及生活质量的影响——一项随机、安慰剂对照试验的荟萃分析
Multidiscip Respir Med. 2022 Aug 3;17:868. doi: 10.4081/mrm.2022.868. eCollection 2022 Jan 12.
10
Flavonoids for Treating Viral Acute Respiratory Tract Infections: A Systematic Review and Meta-Analysis of 30 Randomized Controlled Trials.黄酮类化合物治疗病毒急性呼吸道感染:30 项随机对照试验的系统评价和荟萃分析。
Front Public Health. 2022 Feb 16;10:814669. doi: 10.3389/fpubh.2022.814669. eCollection 2022.